Heron Therapeutics, Inc.
As of Oct 22, 2026, Heron Therapeutics is in Stage 4, the downtrend phase, now in week 33 (since Mar 2, 2026). It closed at $0.30, 79.9% below its 52-week high and below its 200-day average, which is falling.
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is HRTX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
HRTX among Biotechnology454th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …454 | HRTX | Stage 4 · wk 33 | 12 | +3.4% |
Heron Therapeutics: quick answers
What stage is Heron Therapeutics in?
As of Oct 22, 2026, Heron Therapeutics (HRTX) is in Stage 4, the downtrend phase. It entered Stage 4 on Mar 2, 2026 and is in week 33. What the four stages mean
Is Heron Therapeutics in an uptrend?
No. Heron Therapeutics is in a Stage 4 downtrend. It trades 59.1% below its 200-day average, which is falling.
How far is Heron Therapeutics from its 52-week high?
Heron Therapeutics closed at $0.30 on Oct 22, 2026, 79.9% below its 52-week high of $1.49. Its 52-week low is $0.27.
How has Heron Therapeutics performed over the past year?
As of Oct 22, 2026, Heron Therapeutics is down 76.9% over the past year and down 76.2% so far in 2026.
Which sector and industry is Heron Therapeutics in?
Heron Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. Heron Therapeutics, Inc. was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. The company was founded in 1983 and is headquartered in Cary, North Carolina.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.